Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

997124

registered interest
date	29/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Housing: Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to promote public awareness of the the effect on people's health of poor quality indoor environments.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	184965
answer	answer is ministerial correction date of answer 06/11/2018 answer text <p>Public Health England (PHE) raises public awareness of the impacts of indoor air pollution by supporting activities that aim to change behaviour, such as the annual Clean Air Day, and is working with health partners, such as the National Institute for Health and Care Excellence, World Health Organization and Allergy UK, to improve the evidence on the health impacts of poor indoor air quality which will enhance advice to the public. PHE also promotes awareness about carbon monoxide through the use of blog posts, press releases and social media updates.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/11/2018 16:28:25 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

1007757

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Levetiracetam
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effect of the UK leaving the EU on the availability of Keppra for people with epilepsy.
tabling member constituency	Crewe and Nantwich
tabling member printed	Laura Smith
uin	191984
answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>The United Kingdom’s position on medicines regulation remains clear. We want to retain a close working partnership with the European Union to ensure that medicines remain available to UK patients in a safe and timely manner. We have been clear that this involves us making sure our regulators continue to work together, as they do with regulators internationally. As the Prime Minister has said, we intend to to explore with the EU the terms on which the UK could remain part the European Medicines Agency.</p><p> </p><p>Until we can be certain of the outcome of Brexit negotiations our duty as a responsible Government is to prepare for all eventualities, including ‘no deal’. On 23 August 2018, therefore, the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no-deal scenario.</p><p> </p><p>Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.</p><p> </p><p>We understand that the medicine Keppra is important to many people in this country. However, the Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 11:54:10 answering member 4067 label Biography information for Steve Brine
tabling member	4648 label Biography information for Laura Smith

1007762

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has targets for improvements to care and services for people with dementia over the period of this Parliament.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	191881
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>Dementia remains a key priority for the Government. We will implement the Prime Minister’s Challenge on Dementia 2020 (published in February 2015) in full to make sure the lives of those with dementia are transformed by 2020.</p><p> </p><p>Working with our partners, we continue to make progress against the ambitions set in the March 2016 Implementation Plan which details how the commitments in the Challenge, across the four core themes of risk reduction, health and care, awareness and social action, and research will be met. This is reflected in the specific expectation set in the mandate to NHS England 2018/19 that two thirds of people living with dementia should receive a formal diagnosis. As of October 2018, the dementia diagnosis rate was 67.9%.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 20/11/2018 15:37:58 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1409 label Biography information for Mr Gregory Campbell

1007767

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nusinersen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress NHS England, Biogen and NICE have made in discussions on a managed access agreement for the use of Spinraza for the treatment of spinal muscular dystrophy.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	191928
answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).</p><p> </p><p>NICE is in discussion with Biogen (the company that manufactures Spinraza) to determine if there are any commercial flexibilities that could support the company in putting forward a cost-effective price in order for NICE to recommend use of the drug as a clinically and cost-effective use of NHS resources.</p><p> </p><p>NHS England has published an Interim Policy Statement determining the circumstances in which existing patients will be supported to access Spinraza through the Expanded Access Programme (EAP) scheme sponsored by Biogen. The policy statement enables existing patients with type 1 SMA to access Spinraza in advance of NICE’s guidance, although the company has now withdrawn the EAP for newly diagnosed patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 15:13:09 answering member 4067 label Biography information for Steve Brine
tabling member	4249 label Biography information for Anne Marie Morris

1007772

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, if he will publish the review of risk factors and associated vulnerabilities among women recruited to the trial.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191929
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191930 191931 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007773

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: drugs, if he will publish the outcome of the interviews with women to explore the facilitators and barriers to accessing the HIV pre-exposure prophylaxis.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191930
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191931 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007774

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans to publish the long-term plan for the NHS.
tabling member constituency	Washington and Sunderland West
tabling member printed	Mrs Sharon Hodgson
uin	191894
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>The Government expects National Health Service leaders, clinicians and experts to develop the long-term plan to ensure that the NHS can cope with the serious demand and cost pressures it faces in the future. It will be published later this year.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 20/11/2018 11:14:52 answering member 1585 label Biography information for Stephen Hammond
tabling member	1521 label Biography information for Mrs Sharon Hodgson

1007775

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women have joined the HIV pre-exposure prophylaxis impact trial to date.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191931
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191930 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007776

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women who are victims of domestic violence have joined the HIV pre-exposure prophylaxis impact trial to date.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191932
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191930 191931 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1006860

registered interest
date	14/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Surgery
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect on patient outcomes of delaying access to elective surgical procedures on the basis of (a) body weight and (b) smoking status.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	191434
answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>Clinical commissioning groups are responsible for commissioning care that will provide the best possible outcomes for their patients. In doing so, they should take into account best practice and National Institute for Health and Care Excellence guidance. No such assessment has been made by the Department or NHS England.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 11:43:09 answering member 4067 label Biography information for Steve Brine
tabling member	4471 label Biography information for Rachael Maskell